​

Funding Round

Series D - CANbridge Pharmaceuticals

Series D - CANbridge Pharmaceuticals

Investment Firm

Overview

CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare .

Announced Date

Feb 18, 2020

Closed on Date

Feb 18, 2020

Funding Type

Series D

Highlights

Location

Asia

Social

Investor Lead

General Atlantic

General Atlantic

General Atlantic is a early_stage_venture and late_stage_venture and private_equity firm.

Participant Investors

5

Investor Name
Participant InvestorYuanMing Capital
Participant InvestorTigermed
Participant InvestorHudson Bay Capital Management
Participant InvestorRA Capital Management
Participant InvestorGeneral Atlantic

Round Details and Background

CANbridge Pharmaceuticals raised $98000000 on 2020-02-18 in Series D

CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare .

Company Funding History

6

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Dec 01, 2020
Series E - CANbridge Pharmaceuticals
11-43.0M
May 23, 2017
Series B - CANbridge Pharmaceuticals
7-25.0M
Oct 27, 2015
Series A - CANbridge Pharmaceuticals
1-10.0M
Dec 02, 2014
Series A - CANbridge Pharmaceuticals
2-10.0M

Recent Activity

News

Feb 18, 2020

CANbridge Pharmaceuticals Inc. - CANbridge Pharmaceuticals Completes US$98 Million Series D Financing